TickerHumSide-by-side comparison
Merck & Co. vs Pfizer
As of Nov 11, 2026, P/E is 148.7x for Merck & Co. vs 42.1x for Pfizer; P/S is 5.4x for Merck & Co. vs 2.6x for Pfizer; revenue growth is 4.9% for Merck & Co. vs 1.3% for Pfizer; net margin is 3.6% for Merck & Co. vs 6.3% for Pfizer.
What stands out
- Pfizer is cheaper on earnings: 42.1x P/E vs 148.7x for Merck & Co..
- Pfizer carries less debt relative to equity: 0.67 vs 1.11 for Merck & Co..
- Merck & Co.'s shares did better over the past year: +60.9% vs +13.8% for Pfizer.
Key metrics
| Metric | MRK | PFE |
|---|---|---|
| Price | $147.18 | $29.45 |
| Market cap | $362.83B | $167.86B |
| P/E | 148.7x (#2) | 42.1x (#1) |
| P/S | 5.4x (#2) | 2.6x (#1) |
| Revenue growth | 4.9% (#1) | 1.3% (#2) |
| Operating margin | — | — |
| Net margin | 3.6% (#2) | 6.3% (#1) |
| Debt / equity | 1.11 (#2) | 0.67 (#1) |
| 1-year return | +60.9% (#1) | +13.8% (#2) |
| Research score | 50/100 (#2) | 51/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General
- Pfizer Inc. (PFE) — Drug Manufacturers—General